1. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, 2007.
2. Mannino DM. Surveillance for asthma – United States, 1988–1999. MMWR Morb. Mortal. Wkly Rep 2002; 51: 1–13.
3. Price D, Fletcher M, van der Molen T et al. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24 (14009).
4. www.who.int/mediacentre/factsheets/fs307/ru/
5. Bickelmann AG, Burwell CS, Robin ED, Whaley RD. Extreme obesity associated with alveolar hypoventilation; a Pickwickian syndrome. Am J Med 1956; 21 (5): 811–8.
6. Потемкин В.В. Эндокринология. М.: Медицина, 1986.
7. Food and agriculture organization of the united nations. Rome, 2013. Доклад ООН, 2013.
8. Tantisira KG, Weiss ST. Complex interactions in complex traits: obesity and asthma. Thorax 2001; 56 (Suppl. 2): ii64–73.
9. Dixon AE, Holguin F, Sood A et al. An official American Thoracic Society Workshop report: obesity and asthma. Proc Am Thorac Soc 2010; 7 (5): 325–35.
10. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259 (5091): 87–91.
11. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112 (12): 1785–8.
12. Murphy A, Tantisira KG, Soto-Quirós ME et al. PRKCA: a positional candidate gene for body mass index and asthma. Am J Hum Genet 2009; 85 (1): 87–96.
13. Tremblay K, Lemire M, Provost V et al. Association study between the CX3CR1 gene and asthma. Genes. Immun 2006; 7 (8): 632–9.
14. Sirois-Gagnon D, Chamberland A, Perron S et al. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring) 2011; 19 (1): 222–7.
15. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444 (7121): 860–7.
16. Nguyen MT, Satoh H, Favelyukis S et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005; 280 (42): 35361–71.
17. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389 (6651): 610–4.
18. Heijink IH, Vellenga E, Borger P et al. Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells. Immunology 2002; 107 (3): 316–24.
19. Pretolani M, Goldman M. Cytokines involved in the downregulation of allergic airway inflammation. Res Immunol 1997; 148 (1): 33–8.
20. Chin-Chance C, Polonsky KS, Schoeller DA. Twenty-four-hour leptin levels respond to cumulative short-term energy imbalance and predict subsequent intake. J Clin Endocrinol Metab 2000; 85 (8): 2685–91.
21. Boulet LP. Influence of comorbid conditions on asthma. Eur Res J 2009; 33 (4): 897–906.
22. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Res. Med 2007; 101 (11): 2240–7.
23. Saint-Pierre P, Bourdin A, Chanez P et al. Are overweight asthmatics more difficult to control? Allergy 2006; 61 (1): 79–84.
24. Sutherland ER, Goleva E, Strand M et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008; 178 (7): 682–7.
25. Boulet LP. Asthma and obesity. Clin Exp Allergy 2013; 43 (1): 8–21.
26. Theron AJ, Steel HC, Tintinger GR et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res 2014.
27. Giouleka P, Papatheodorou G, Lyberopoulos P et al. Body mass index is associated with leukotriene inflammation in asthmatics. Eur J Clin Invest 2011; 41 (1): 30–8.
28. Peters-Golden M, Swern A, Bird SS et al. Influence of body mass index on the response to asthma controller agents. Eur Res J 2006; 27 (3): 495–503.
29. Theron AJ, Gravett CM, Steel HC et al. Leukotrienes C4 and D4 sensitize human neutrophils for hyperreactivity to chemoattractants. Inflamm Res 2009; 58 (5): 263–8.
30. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31; 5: 360–7.
31. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007; 67 (6): 887–901.
32. Holme H, Winckworth LC. Montelukast can reduce the severity and extent of atopic dermatitis. J Paediatr Child Health 2013; 49 (5): 412–5.
33. Kosnik M, Subic T. Add-on montelukast in antihistamine-resistant chronic idiopathic urticarial. Res Med 2011; 105 (Suppl. 1): S84–88.
34. Riccioni G, Bucciarelli T, Mancini B et al. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007; 14 (18): 1966–77.
35. Zuberbier T, Aberer W, Asero R et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69 (7): 868–87.
36. Di Gennaro A, Haeggström JZ. The leukotrienes: immune-modulating lipid mediators of disease. Adv Immunol 2012; 116: 51–92.
37. Scichilone N, Battaglia S, Benfante A, Bellia V. Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients. Clin Int Aging 2013; 8: 1329–37.
38. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2014. CADTH Rapid Response Reports.
39. Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics 2012; 130 (3): e575–580.
40. Scott HA, Gibson PG, Garg ML et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial. Clin Exp Allergy 2013; 43 (1): 36–49.
41. Adeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev 2012; 7: CD009339.
42. Moreira A, Bonini M, Garcia-Larsen V et al. Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I). Allergy 2013; 68 (4): 425–39.
Авторы
Н.В.Шартанова1, Т.Н.Суровенко2, Е.Ф.Глушкова1
1 ФГБУ ГНЦ Институт иммунологии ФМБА России;
2 ГБОУ ВПО Тихоокеанский государственный медицинский университет Минздрава России